Login / Signup

Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022.

Elisabeth Lea VikseEven FossumMagnhild Sekse ErdalOlav HungnesKaroline Bragstad
Published in: Influenza and other respiratory viruses (2023)
New immune evasive variants of SARS-CoV-2 continue to emerge, potentially causing new waves of covid-19 disease. Here, we evaluate levels of neutralizing antibodies against isolates of Omicron variants, including BQ.1.1 and XBB, in sera harvested 3-4 weeks after vaccination or breakthrough infections. In addition, we evaluate neutralizing antibodies in 32 sera from October 2022, to evaluate immunity in Norwegian donors prior to the winter season. Most serum samples harvested in October 2022 had low levels of neutralizing antibodies against BQ.1.1 and especially XBB, explaining why these variants and their descendants have dominated in Norway during the 2022 and 2023 winter season.
Keyphrases
  • sars cov
  • dengue virus
  • copy number
  • respiratory syndrome coronavirus
  • zika virus
  • coronavirus disease
  • gene expression
  • kidney transplantation